Skip to main content

Peer Review reports

From: AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer

Original Submission
30 Apr 2021 Submitted Original manuscript
2 Aug 2021 Author responded Author comments - Andrew Oar
Resubmission - Version 2
2 Aug 2021 Submitted Manuscript version 2
6 Aug 2021 Editorially accepted
19 Aug 2021 Article published 10.1186/s12885-021-08666-y

You can find further information about peer review here.

Back to article page